MedTrace Logo

ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer

NCT04792892 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2023-12-08

No results posted yet for this study

Summary

Anal cancer is a rare disease, but the incidence is rising. About 200 patients will get this type of cancer yearly in Sweden. Curative treatment includes chemotherapy and radiotherapy. The prognosis is good, but some patients will have recurrent or persistent disease after concluded chemo-radiotherapy and will then be offered salvage surgery. Some patients develop distant metastases that can be treated with good results.

The aim of this study is to identify and describe functional outcome in patients diagnosed with anal cancer. We will study patients from diagnosis, try to identify early toxicity to treatment and then identify long-term morbidity.

Conditions

Interventions

OTHER

Questionnaires

Patients will be answering questionnaires at 0, 3, 12, 36, 60 and 120 months

Sponsors & Collaborators

  • Sahlgrenska University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2025-04-01
Completion
2035-04-01

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04792892 on ClinicalTrials.gov